Question

Case 14-10
In-Process Research & Development

Bust-A-Knee Inc. (Bust-A-Knee) is a medical device company that specializes in developing knee replacement hardware. In 2020, Bust-A-Knee acquired 100 percent equity ownership of MD International (MD) for a purchase price of $15 million. MD is a pharmaceutical company that is developing two drugs: (1) a drug to cure cancer, Drug X, and (2) a pain medication, OuchX. Bust-A-Knee acquired the entity to expand into a new sector within the medical field.

Bust-A-Knee concluded the acquisition of MD was a business acquisition. In purchase accounting, Bust-A-Knee recognized intangible assets for the in-process research and development (IPR&D) related to the ongoing development of Drug X and OuchX, among other acquired intangible assets. Drug X and OuchX had an acquisition-date fair value of $4 million and $3 million, respectively.

During 2021, Bust-A-Knee determined its operations could not support the continued development of Drug X because significant efforts were being put forth in the development of OuchX. Since the date of acquisition, Bust-A-Knee had not invested any additional funding in the development of Drug X. Bust-A-Knee determined that there was no change in the carrying amount recorded at the date of acquisition.

Rather than abandon the development project, Bust-A-Knee entered into an agreement with Pharmers Company (Pharmers) to transfer its ownership interests in the IPR&D for Drug X. Pharmers, the market’s largest pharmaceutical company, will use Drug X’s IPR&D to continue its development, and obtain FDA approval to sell the drug on the open market. The transfer of the IPR&D from Bust-A-Knee to Pharmers is known as an out-license transfer, which is essentially a sale agreement.

In return, Pharmers will pay Bust-A-Knee (1) a nonrefundable fixed fee of $2 million at contract execution; (2) the ability to earn a contingent future payment of $500,000, when Drug X is FDA approved; and (3) a 10 percent royalty fee based on the annual sales earned by Pharmers for the sale of Drug X in each of the subsequent five years following FDA approval.

At the date of transfer, Bust-A-Knee estimates the fair value of the total consideration (nonrefundable fixed fee and contingent future fees) to be $5.5 million, which assumes FDA approval is granted. Pharmers transfers $2 million for the ownership of the IPR&D of Drug X.

Required:

• At the date of transfer to Pharmers, how should Bust-A-Knee record the transaction? PLEASE PROVIDE CODIFICATION AS WELL, THANK YOU

Answer 1

Given he Infosmahon nonsefundable fked fee of 2 milion at comtsack c&ecution tvse payment of 580 eam a Contimgent a o pexcent soylty fee based on he annual sales. Ai fnceplion of the Conksact, tha i cegn zes a nception of net loss of $45 milon 5 million of considesalion, less he in- psecess seaseasch and development asset of 50milon entity sea ssesses he tsamsaclion paice at each sepostig esíod to detešmine whethex ỉį.spxobable Hata significant sevessal uld not accox fsom Sscegmizing He es占mates as a%es home and, 1f so,seco nzes sanSaction Other income i accesdance cd a aasaphS 82-45. ASU hal mount as GOG-10-32-іч and GOG-lo-32-42.thšou 2014-iq